HomeCompareDEXSF vs MRK

DEXSF vs MRK: Dividend Comparison 2026

DEXSF yields 5.97% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $33.5K in total portfolio value
10 years
DEXSF
DEXSF
● Live price
5.97%
Share price
$4.14
Annual div
$0.25
5Y div CAGR
-19.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.3K
Annual income
$82.66
Full DEXSF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — DEXSF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDEXSFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DEXSF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DEXSF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DEXSF
Annual income on $10K today (after 15% tax)
$507.76/yr
After 10yr DRIP, annual income (after tax)
$70.26/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,258.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DEXSF + MRK for your $10,000?

DEXSF: 50%MRK: 50%
100% MRK50/50100% DEXSF
Portfolio after 10yr
$40.0K
Annual income
$4,940.40/yr
Blended yield
12.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

DEXSF
No analyst data
Altman Z
1.3
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DEXSF buys
0
MRK buys
0
No recent congressional trades found for DEXSF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDEXSFMRK
Forward yield5.97%2.76%
Annual dividend / share$0.25$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-19.3%32.7%
Portfolio after 10y$23.3K$56.8K
Annual income after 10y$82.66$9,798.13
Total dividends collected$2.4K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DEXSF vs MRK ($10,000, DRIP)

YearDEXSF PortfolioDEXSF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,182$482.07$11,206$366.19$24.00MRK
2$12,371$406.56$12,650$502.35$279.00MRK
3$13,577$339.24$14,407$694.19$830.00MRK
4$14,808$280.78$16,585$967.82$1.8KMRK
5$16,075$230.97$19,342$1,363.89$3.3KMRK
6$17,390$189.11$22,913$1,947.19$5.5KMRK
7$18,761$154.29$27,662$2,823.89$8.9KMRK
8$20,200$125.55$34,159$4,173.35$14.0KMRK
9$21,716$101.95$43,337$6,308.80$21.6KMRK
10$23,319$82.66$56,776$9,798.13$33.5KMRK

DEXSF vs MRK: Complete Analysis 2026

DEXSFStock

Dexus is one of Australia's leading real estate groups, proudly managing a high-quality Australian property portfolio valued at $44.3 billion. We believe that the strength and quality of our relationships will always be central to our success and are deeply committed to working with our customers to provide spaces that engage and inspire. We invest only in Australia, and directly own $16.5 billion of office and industrial properties. We manage a further $15.6 billion of office, retail, industrial and healthcare properties for third party clients. The group's $11.4 billion development pipeline provides the opportunity to grow both portfolios and enhance future returns. With 1.6 million square metres of office workspace across 51 properties, we are Australia's preferred office partner. Dexus is a Top 50 entity by market capitalisation listed on the Australian Securities Exchange (trading code: DXS) and is supported by more than 29,000 investors from 24 countries. With 36 years of expertise in property investment, development and asset management, we have a proven track record in capital and risk management, providing service excellence to tenants and delivering superior risk adjusted returns for investors.

Full DEXSF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this DEXSF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DEXSF vs SCHDDEXSF vs JEPIDEXSF vs ODEXSF vs KODEXSF vs MAINDEXSF vs JNJDEXSF vs ABBVDEXSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.